ABBV-383
A Multicenter, Phase 1b, Open-label Study of ABBV-383 Administered Subcutaneously in Subjects With Relapsed or Refractory Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 55 patients (estimated)
- Sponsors
- AbbVie
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA), CD3
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1999
- NCT Identifier
- NCT06223516
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.